Lakewood-Amedex Biotherapeutics Inc. LABT
—
1.67
(0.16)
(8.74%)
as of 25 Sep
- Market cap
- $4.3M
- P/E
- 0.0×
Follow LABT
| Jun '26 | Mar '26 | Dec '25 | Jun '25 | Older periods | |
|---|---|---|---|---|---|
Current Ratio |
7.70 | 0.02 | 0.13 | — |
+2 more quarters Free account |
Net Debt/EBITDA |
1.22 | 0.01 | 0.00 | 0.00 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | — | — | |
Operating CF/Net income |
0.54 | 0.25 | 0.00 | 0.44 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
0.00 | 0.00 | — | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | — | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | — | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | — | 0.00% | |
Free Cash Flow per Share |
(1.48) | (0.50) | 0.00 | (0.73) | |
Cash per Share |
3.23 | 0.02 | 0.00 | 0.00 | |
Shareholders Equity per Share |
3.05 | (4.06) | 0.00 | 0.00 | |
Interest Debt per Share |
0.00 | 0.00 | — | 0.00 | |
Book value per Share |
3.05 | (4.06) | 0.00 | 0.00 | |
Free Cash Flow |
(2.10) | (0.35) | (1.94) | (0.51) | |
Working Capital |
4.22 | (2.98) | (2.10) | — | |
Capital Expenditures |
— | — | 0.00 | — | |
Net Current Asset Value |
4.22 | (2.99) | (2.14) | 0.00 | |
| Other line items | |||||
Quick Ratio |
7.30 | 0.00 | 0.10 | — | |
Revenue per Share |
0.00 | 0.00 | — | 0.00 | |
Operating CF per Share |
(1.48) | (0.50) | 0.00 | (0.73) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Assets |
2.48 | 0.63 | — | — | |
Capex to Sales |
— | — | 0.00 | — | |
Net Profit Margin |
0.00% | 0.00% | — | 0.00% |
Columns are period end dates